Find a Tender
complete
Official procurement procedure
Framework for QC Analytical Testing Requirements
Analysis services
Published value
Not published
Submission deadline Not published
Lots published6
Procurement Executive Summary
AI & Search Synopsis
Generated from official OCDS record
Tenderline Synopsis: Centre for Process Innovation Limited: "Framework for QC Analytical Testing Requirements". Published status: complete. Published value: Value not published. 6 published lots. Submission deadline not published. See the official notice for participation instructions.
| Contracting Authority | Centre for Process Innovation Limited | Scope & Categories | Not published | Submission Window | complete No deadline published |
|---|---|---|---|---|---|
| Submission Gateway | Direct notice route | Legal Basis & Regime | Standard procurement | Estimated Value (exc. VAT) | Not published |
Bidder Intelligence · Authority Profile: Centre for Process Innovation Limited
Market Analytics
Derived from OCDS awards & bid statistics
Published history for Centre for Process Innovation Limited. These figures describe retained records, not a forecast of bids or a measure of buyer bias.
Published-to-award variance
Not availableInsufficient comparable data
Competition Density
2.1Bids / Report
Supplier ConcentrationNo estimate
Insufficient attributable awardsNo concentration estimate availablePayment Terms
Check noticePublished terms
Coverage: 68 active published awards; 68 bid reports (which may be per lot). Supplier values exclude multi-supplier awards, frameworks and DPS, and use GBP only. They are published award values, not payments. Published-to-award variance compares single-lot, single-award, single-supplier GBP procedures with explicitly non-framework/non-DPS status; increases remain in the average. Unpublished data stays unknown. Awarded suppliers are winners, not all bidders.
Procedure terms
Contracting AuthorityCentre for Process Innovation Limited | Procedure methodNot published | Procurement categoryNot published |
Statuscomplete | Framework / DPSNot published | CompetitionNot published |
Above thresholdNot published | Legal basisNot published | Tender period startsNot published |
Clarification deadlineNot published | Electronic submissionNot published | Submission languagesNot published |
Published22 May 2025, 09:01 BST | Last source update22 May 2025, 09:01 BST | Recurring procurementNot published |
ClassificationAnalysis services | ||
Delivery area | ||
OCIDocds-h6vhtk-0489eb | ||
What is being bought
You are invited to submit a tender for the following requirements; analytical services for multiple modalities drug substances and drug products required for early phase clinical trials. This tender is to cover the analytical services required for release analysis of drug substance (DS) and drug product (DP).
What changed
From the official release history
- Status changed to complete
22 May 2025, 09:01 BST - Official notice release published
22 May 2025, 09:01 BST - Submission deadline changed to published date
22 May 2025, 09:01 BST - Status changed to active
12 Aug 2024, 14:35 BST - Official notice release published
12 Aug 2024, 14:35 BST - Submission deadline changed to 12 Sept 2024, 12:00 BST
12 Aug 2024, 14:35 BST - Buyer information updated
12 Aug 2024, 14:35 BST
Lots and requirements (6)
Published by the contracting authority
- Lot 1 · #1Water Testing (Glasgow Area)cancelledPublished valueNot publishedThe MMIC facility near Glasgow will require microbiological testing of water samples in accordance with Ph. Eur. [0169]. The following analysis techniques are required and have been included in pricing schedule for comparison: -Microbiological monitoring (Ph. Eur.) -Bacterial endotoxin testing (Ph. Eur.)Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 2 · #2RNA Therapeutic/VaccinescancelledPublished valueNot publishedOur facility in Darlington currently manufactures RNA-LNP vaccines and therapeutics for Phase 1 clinical trials. Both the drug substance and drug product are presented as liquid formulations. The requirements for RNA-LNP analysis include: - Method development, verification and Phase appropriate validation (as required) - Integrity analysis for RNA In-process samples, RNA-LNP drug substance and drug product (release and stability analysis) - Process impurity testing for RNA-LNP drug substance and drug productContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 3 · #3Recombinant Protein TherapeuticscancelledPublished valueNot publishedOur facility in Darlington will, in the future, manufacture Recombinant protein vaccines and therapeutics produced in Microbial cell lines, for Phase 1 clinical trials. Both the drug substance and drug product are presented as liquid formulations. The requirements for Recombinant Protein analysis include: - Method development, verification and Phase appropriate validation (as required) - Integrity analysis for Recombinant Protein drug substance and drug product (release and stability analysis) - Process impurity testing for Recombinant Protein drug substance and drug productContract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 4 · #4Process and Product Microbiology (Teesside Area)cancelledPublished valueNot publishedOur facility in Darlington will require Microbiology testing to support the RNA-LNP and Recombinant Protein GMP manufacture. The following analysis is required, all under Ph.Eur: - Endotoxin (Buffers) - Endotoxin (Process product Protein) - Endotoxin (Process product RNA and RNA-LNP) - Bioburden (Buffers) - Bioburden (Process product Protein) - Bioburden (Process product RNA and RNA-LNP)Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 5 · #5Process and Product Microbiology (Glasgow Area)cancelledPublished valueNot publishedOur facility in Glasgow will require Microbiology testing to support the GMP manufacturing of oligonucleotide therapies. The following analysis is required, all under Ph.Eur: - Endotoxin (Process product oligonucleotide) - Bioburden (Process product oligonucleotide)Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
- Lot 6 · #6OligonucleotidescancelledPublished valueNot publishedThe facility at MMIC will manufacture both single and double stranded novel oligonucleotides for early phase clinical trials. The drug substance (API) may be a lyophilised powder or solution API and the finished drug product may be a solid or liquid formulation. The requirements for oligonucleotides analysis include: - Chemical analysis for oligonucleotide drug substance and drug product (release and stability analysis) - Method development, verification and phase appropriate validation (as required)Contract periodNot publishedEligibilityNot publishedOptions / renewalNot published
Timeline
- Procedure published
22 May 2025, 09:01 BST - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Award active
Not published · Not published - Contract active
Signed 28 Apr 2025, 00:00 BST · £1,000,000 - Contract active
Signed 28 Apr 2025, 00:00 BST · £1,000,000 - Contract active
Signed 28 Apr 2025, 00:00 BST · £1,000,000 - Contract active
Signed 28 Apr 2025, 00:00 BST · £1,000,000 - Contract active
Signed 28 Apr 2025, 00:00 BST · £1,000,000 - Contract active
Signed 4 Mar 2025, 00:00 GMT · £1,000,000
Commercial outcome and competition
Awards Assured Micro Ltd, Reading Scientific Serices Ltd, Wickham Micro Ltd Not published · Not published · active ITS Testing Services (UK) Ltd trading as Intertek P&IA, Reading Scientific Serices Ltd, SGS UK Ltd Not published · Not published · active ITS Testing Services (UK) Ltd trading as Intertek P&IA, Reading Scientific Serices Ltd, SGS UK Ltd Not published · Not published · active Reading Scientific Serices Ltd, SGS UK Ltd, Wickham Micro Ltd Not published · Not published · active Assured Micro, Reading Scientific Serices Ltd, Wickham Micro Ltd Not published · Not published · active CatSci Ltd, ITS Testing Services (UK) Ltd trading as Intertek P&IA, Reading Scientific Serices Ltd Not published · Not published · active |
Contracts RNA Therapeutic/Vaccines £1,000,000 · signed 28 Apr 2025, 00:00 BST · active Recombinant Protein Therapeutics £1,000,000 · signed 28 Apr 2025, 00:00 BST · active Process and Product Microbiology (Teesside Area) £1,000,000 · signed 28 Apr 2025, 00:00 BST · active Process and Product Microbiology (Glasgow Area) £1,000,000 · signed 28 Apr 2025, 00:00 BST · active Oligonucleotides £1,000,000 · signed 28 Apr 2025, 00:00 BST · active Water Testing (Glasgow Area) £1,000,000 · signed 4 Mar 2025, 00:00 GMT · active |
Bid statistics bids: 4 (lot 1) electronicBids: 4 (lot 1) foreignBidsFromEU: 0 (lot 1) foreignBidsFromNonEU: 4 (lot 1) smeBids: 4 (lot 1) bids: 3 (lot 2) electronicBids: 3 (lot 2) foreignBidsFromEU: 0 (lot 2) foreignBidsFromNonEU: 3 (lot 2) smeBids: 3 (lot 2) bids: 3 (lot 3) electronicBids: 3 (lot 3) foreignBidsFromEU: 0 (lot 3) foreignBidsFromNonEU: 3 (lot 3) smeBids: 3 (lot 3) bids: 3 (lot 4) electronicBids: 3 (lot 4) foreignBidsFromEU: 0 (lot 4) foreignBidsFromNonEU: 3 (lot 4) smeBids: 3 (lot 4) bids: 3 (lot 5) electronicBids: 3 (lot 5) foreignBidsFromEU: 0 (lot 5) foreignBidsFromNonEU: 3 (lot 5) smeBids: 3 (lot 5) bids: 6 (lot 6) electronicBids: 6 (lot 6) foreignBidsFromEU: 0 (lot 6) foreignBidsFromNonEU: 6 (lot 6) smeBids: 6 (lot 6) |
Buyer and organisations in this procedure
Centre for Process Innovation Limited
Contracting authority GB-FTS-3317Documents (0)
Official links; attachments are not copied
No linked documents are published
Related procedures (0)
No related procedures published